Lentiviral Vector Upstream Process

Lentiviral vectors (LVs) are essential tools for gene and cell therapies thanks to their ability to efficiently transduce dividing and nondividing cells and integrate stably into host genomes. Yet, scaling LV production for commercial use remains a major challenge. Traditional adherent HEK 293 systems and transient transfection methods are costly and difficult to scale, driving a shift toward serum-free suspension cultures and stable-inducible producer cell lines. These approaches reduce variability, simplify workflows, and enable true scale-up in stirred-tank bioreactors. This application note demonstrates a streamlined, animal-component-free process using suspension-adapted HEK 293 cells, achieving linear scalability from 5 L to 28 L.

Explore how these innovations can help meet growing demand for LV-based therapies.